Advanced glycation end-products as long-term predictors of death and reinfarction after an acute coronary syndrome.
OBJECTIVE
We evaluated the prognostic value of plasmatic fluorescent advanced glycation end-products (AGE) to predict long-term death and reinfarction in patients with acute coronary syndrome (ACS).


METHODS
A unicenter registry comprising a prospective cohort of 210 ACS patients (47.4% ST-segment elevation myocardial infarction) followed up during 3.1 ± 0.9 years were carried out.


RESULTS
Cardiovascular death ratio was 5.7% and 23 patients suffered reinfarction (11.0%). The hazard ratio of the multivariate analysis with respect to death and reinfarction for AGE adjusted by GRACE risk score was 1.011 (1.006-1.016), p < 0.001.


CONCLUSIONS
Fluorescent AGE plasma levels were an independent predictor of death and reinfarction in the long-term follow-up of patients with ACS.
Servicio de Cardiología, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
Sergio
S
Raposeiras-Roubín
Bruno K
BK
Rodino-Janeiro
Beatriz
B
Paradela-Dobarro
Haidara
H
Almansour
Lilian
L
Grigorian-Shamagian
María V
MV
Reino-Maceiras
José M
JM
García-Acuña
José R
JR
González-Juanatey
Ezequiel
E
Álvarez
D054058:Acute Coronary Syndrome / Q000097:blood / Q000175:diagnosis* / Q000401:mortality*; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000175:diagnosis*; D011379:Prognosis; D012008:Recurrence
D017127:Glycation End Products, Advanced
acute coronary syndrome; advanced glycation end-products; cardiovascular diabetic complications; cardiovascular mortality; cardiovascular risk biomarkers